Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | SDCBP | O00560 | 1/20 | 0.46 |
| ▸ | SDC2 | P34741 | 1/20 | 0.46 |
| ▸ | KDM4A | O75164 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | RORC | P51449 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30736827 | 0.95 | HDAC1 (0.58) | EPHX2NR1H4L3MBTL1HDAC1GAA | |
| SCHEMBL26130392 | 0.90 | POLB (0.57) | EPHX2NR1H4L3MBTL1HDAC1NAMPT | |
| SCHEMBL3180689 | 0.90 | L3MBTL1 (0.61) | L3MBTL1HDAC1GAANAMPTCA1 | |
| SCHEMBL27426150 | 0.87 | L3MBTL1 (0.53) | EPHX2NR1H4L3MBTL1HDAC1GAA | |
| SCHEMBL11521521 | 0.86 | L3MBTL1 (0.55) | L3MBTL1HDAC1GAANAMPTCA1 | |
| SCHEMBL8611284 | 0.86 | L3MBTL1 (0.52) | L3MBTL1HDAC1GAANAMPTCA1 | |
| SCHEMBL5209897 | 0.86 | L3MBTL1 (0.52) | L3MBTL1HDAC1GAANAMPTCA1 | |
| SCHEMBL5595267 | 0.85 | L3MBTL1 (0.49) | EPHX2NR1H4L3MBTL1HDAC1GAA | |
| SCHEMBL2787151 | 0.85 | GLS (0.58) | HDAC1NAMPTCA1CA12CA7 | |
| SCHEMBL3838871 | 0.85 | CA12 (0.63) | L3MBTL1HDAC1NAMPTCA1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4563146-A1 | FLAVIVIRUS INHIBITORS | IRBM S.P.A. (IT) | 2025-06-04 | — | — | EP | disclosed |
| US-20250170253-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (US) | 2025-05-29 | — | — | US | disclosed |
| US-20240350643-A1 | PROTEIN DEGRADATION AGENT | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2024-10-24 | — | — | US | disclosed |
| CN-118290446-A | Compound for inhibiting and degrading c-MYC and medical application thereof | 西藏海思科制药有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-118084881-A | PROTAC small molecules, pharmaceutical composition and application thereof | 南京正济医药研究有限公司 | 2024-05-28 | — | — | CN | disclosed |
| EP-4361141-A1 | PROTEIN DEGRADATION AGENT | Suzhou Kintor Pharmaceuticals, Inc. (CN) | 2024-05-01 | — | — | EP | disclosed |
| CN-117545749-A | Protein degradation agent | 苏州开拓药业股份有限公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-115504963-A | C-Myc protein degradation agent | 苏州开拓药业股份有限公司 | 2022-12-23 | — | — | CN | disclosed |
| US-20220265841-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE, INC. | 2022-08-25 | — | — | US | disclosed |
| EP-3875082-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | Endocyte, Inc. (US) | 2021-09-08 | — | — | EP | disclosed |
| EP-1216236-A1 | TRYPTASE INHIBITORS | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2002-06-26 | — | — | EP | disclosed |
| WO-2002047762-A1 | SERINE PROTEASE INHIBITORS | TULARIK LIMITED (GB) | 2002-06-20 | — | — | WO | disclosed |
| EP-1192135-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2001027096-A9 | AMINOMETHYL-(HETERO)ARYL DERIVATIVES AND THEIR USE AS TRYPTASE INHIBITORS | PROTHERICS MOLECULAR DESIGN LT (GB) | 2001-07-12 | — | — | WO | disclosed |
| WO-2001044226-A1 | SERINE PROTEASE INHIBITORS | TULARIK LIMITED (GB) | 2001-06-21 | — | — | WO | disclosed |
| WO-2001027096-A1 | AMINOMETHYL-(HETERO)ARYL DERIVATIVES AND THEIR USE AS TRYPTASE INHIBITORS | TULARIK LIMITED (GB) | 2001-04-19 | — | — | WO | disclosed |
| WO-2001019809-A1 | TRYPTASE INHIBITORS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2001-03-22 | — | — | WO | disclosed |
| WO-2000076970-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-2000077027-A2 | SERINE PROTEASE INHIBITORS | TULARIK LIMITED (GB) | 2000-12-21 | — | — | WO | disclosed |
| US-4159373-A | 7-Acyl-3-(sulfonic acid and sulfamoyl substituted tetrazolyl thiomethyl) cephalosporins | SMITHKLINE CORPORATION (US) | 1979-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240350643-A1 | PROTEIN DEGRADATION AGENT | MYC, MYCBP, MYCBP2 | EPHX2 4529/4885NR1H4 4290/4885L3MBTL1 1166/4885 |
| US-20220265841-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | EPHX2 1280/4885NR1H4 203/4885L3MBTL1 986/4885 |
| US-20250170253-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | EPHX2 1280/4885NR1H4 203/4885L3MBTL1 986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.